Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Dec 17, 2019 (7 years ago)

Ketorolac Tromethamine Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Ketorolac Tromethamine Injection, USP 30 mg/mL, packaged in 1 mL Single Dose Vials (NDC 0641-6042-01), 25 vials/shelf-pack (NDC 0641-6042-25), For IV or IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Affected NDCs 0641-6042-01 0641-6042-25

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ketorolac Tromethamine
NDC 00641-6042
30 mg/mL Injection
Intramuscular|intravenous
Hikma Pharmaceuticals USA Inc. Rx
Recalling firm
Hikma Pharmaceuticals USA Inc.
NDC code
0641-6042-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0864-2020 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by Hikma Pharmaceuticals USA Inc.

All 2019 recalls
Class II · Moderate risk

Ramipril Capsules USP

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ongoing Impurity / degradation Hikma Pharmaceuticals USA INC. NDC 76282-673-01 D-0831-2026
Class II · Moderate risk

Alendronate Sodium Oral Solution

This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.

Ongoing Wrong potency / content Hikma Pharmaceuticals USA INC NDC 0054-0282-59 D-0526-2026
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Ongoing Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class I · High risk

Acetaminophen Injection

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Ongoing Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9386-01 D-0635-2024